HealthcareServices

Global Allogeneic Cell Therapy Industry Insights: Key Trends and Growth Estimates

February 19, 2026February 19, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the allogeneic cell therapy market from 2026–2035 with trusted insights from The Business Research Company

Across 2026–2030, what is the expected market valuation path of the Allogeneic Cell Therapy Market?

The allogeneic cell therapy market has seen rapid expansion in recent years. Its value is expected to climb from $1.2 billion in 2025 to $1.34 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 11.5%. Historical growth can be ascribed to factors such as the restricted availability of allogeneic cell therapy products, the growth in early-stage clinical trials, an increasing prevalence of hematological disorders, the rising adoption of cell therapies by hospitals, and reliance on donor cell banks.

The allogeneic cell therapy market size is anticipated to experience substantial growth over the coming years. It is projected to reach $1.97 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.2%. This expansion during the forecast period is driven by progress in stem cell and immune cell engineering, the broadening of dermatological and other therapeutic applications, increasing investment in cell therapy manufacturing facilities, collaborations between hospitals and biotech firms, and the adoption of automated cell processing technologies. Significant trends for the forecast period include a growing uptake of stem cell therapies, a heightened focus on T-cell and NK-cell therapies, the expansion of iPSC-based therapeutic applications, an increasing demand for personalized cell therapy treatments, and enhanced regulatory oversight and safety standards.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15976&type=smp

Which Drivers Are Supporting The Rise Of The Allogeneic Cell Therapy Market?

The escalating prevalence of chronic diseases is anticipated to fuel the expansion of the allogeneic cell therapy market. A chronic disease is a persistent health condition typically necessitating ongoing medical attention and can restrict daily activities or diminish quality of life. The increasing occurrence of chronic diseases results from altered habits, inherited factors, and exposure to chemicals, toxins, and airborne pollutants. Allogeneic cell therapy offers substantial potential for treating a broad spectrum of chronic diseases by employing healthy cells from a donor to repair, replace, or modulate dysfunctional cells or tissues in the recipient. For instance, in January 2023, according to the National Center for Biotechnology Information (NCBI), a US-based medicine library, the number of individuals aged 50 and above suffering from one or more chronic illnesses is projected to rise by 99.5% by 2050, increasing from 71.52 million in 2020 to 142.66 million. Therefore, the heightened prevalence of chronic diseases is a primary driver for the growth of the allogeneic cell therapy market.

What Leading Segments Are Studied In The Allogeneic Cell Therapy Market?

The allogeneic cell therapy market covered in this report is segmented –

1) By Type: Stem Cell Therapies, Non-Stem Cell Therapies

2) By Therapeutic Area: Hematological Disorders, Dermatological Disorders

3) By End User: Hospitals, Specialty Clinics

Subsegments:

1) By Stem Cell Therapies: Hematopoietic Stem Cell Therapy (Hematopoietic Stem Cells), Mesenchymal Stem Cell Therapy (MSC-Based Therapies), Induced Pluripotent Stem Cells (iPSC-Based Therapies), Neural Stem Cell Therapy

2) By Non-Stem Cell Therapies: T-cell Therapies, Natural Killer (NK) Cell Therapies, Dendritic Cell Therapies

Which Trends Are Influencing The Performance And Direction Of The Allogeneic Cell Therapy Market?

Major companies in the allogeneic cell therapy market are focusing on developing innovative solutions, such as cell processing platforms, to strengthen their position within the market. Cell processing platforms are systems and technologies utilized to prepare and manipulate cells for therapeutic applications, covering isolation, purification, expansion, modification, and quality control to ensure cells are appropriate for clinical use. For instance, in March 2024, Getinge, a Sweden-based healthcare company, collaborated with CellRev, a UK-based biotechnology company, to introduce Livit ACE, a platform for continuous cell processing (Adherent Cell Expansion). This innovative platform integrates advanced automation and bioprocessing technologies, significantly boosting the efficiency and scalability of cell production. Its unique features include state-of-the-art cell isolation and purification systems that guarantee high cell purity and viability, robust expansion capabilities to produce large quantities of therapeutic cells, sophisticated genetic modification tools for precise cell engineering, and rigorous quality control measures to guarantee the safety and efficacy of the cell products.

Which Major Industry Participants Are Leading The Allogeneic Cell Therapy Market Growth?

Major companies operating in the allogeneic cell therapy market are Novartis AG, Bristol Myers Squibb Company, Takeda Pharmaceutical Company Limited, Bluebird Bio Inc., Poseida Therapeutics Inc., Fate Therapeutics Inc., Fortress Biotech Inc., Sorrento Therapeutics Inc., Eureka Therapeutics Inc., Juno Therapeutics Inc., Adaptimmune Therapeutics plc, Cellectis SA, Ziopharm Oncology Inc., Allogene Therapeutics Inc., Century Therapeutics Inc., Autolus Therapeutics plc, Bellicum Pharmaceuticals Inc., Celyad SA, TILT Biotherapeutics Ltd., CRISPR Therapeutics AG

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/allogeneic-cell-therapy-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Allogeneic Cell Therapy Market?

North America was the largest region in the allogeneic cell therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the allogeneic cell therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Allogeneic Cell Therapy Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15976&type=smp

Browse Through More Reports Similar to the Global Allogeneic Cell Therapy Market 2026, By The Business Research Company

Autologous Cell Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/autologous-cell-therapy-global-market-report

Cells Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/cells-therapy-global-market-report

Cell Therapy Technologies Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-therapy-technologies-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795